ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO822

Role of Angiopoietins in Cardiovascular Disease (CVD) Outcomes of Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical


  • Brown, Liam, Yale School of Medicine, New Haven, Connecticut, United States
  • Gendy, Natalie, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada
  • Staunton, Mary Kate, Yale School of Medicine, New Haven, Connecticut, United States
  • Garg, Kanika K., Yale School of Medicine, New Haven, Connecticut, United States
  • Yamamoto, Yu, Yale School of Medicine, New Haven, Connecticut, United States
  • Obeid, Wassim, Johns Hopkins University, Baltimore, Maryland, United States
  • Bostom, Andrew, Brown University, Providence, Rhode Island, United States
  • Mansour, Sherry, Yale School of Medicine, New Haven, Connecticut, United States

Kidney transplant recipients have 30 times the risk of dying from cardiovascular disease (CVD). We tested the role of 2 vascular biomarkers, angiopoietin-1 and angiopoietin-2 (angpt-1, -2), in the development of CVD in deceased donor kidney transplant recipients.


This is an ancillary analysis of the FAVORIT study, evaluating the associations between baseline levels of angpt-1 and angpt-2 in the development of CVD and the secondary outcomes of graft failure (GF) and death in 2000 recipients. We used a Cox regression analysis to test the associations between biomarker quartiles and outcomes.


Median age of participants was 52 IQR [45, 59] years with 37% women and 73% identifying as white. Median time from transplantation to biomarker measurement was 3.99 IQR [1.58, 7.93] years. Median time to the development of CVD was 3.7 IQR [2.89-5.25] years. Angpt-1 was not significantly associated with outcomes. Higher levels of angpt-2 (quartile 4) as compared to quartile 1 had about 2 times the risk of CVD, GF and death [aHR 1.85 (1.25 - 2.73), P<.01; 2.24 (1.36 - 3.70), P<.01; 2.30 (1.48 - 3.58), P<.01, respectively, (Figure 1)].


Angpt-2 may identify high-risk kidney transplant recipients for the development of CVD. This may aid in tailoring follow-up after transplantation to reduce the risk of CVD.

The red line represents the probability of not developing CVD in patients with quartile 1 of angiopoietin-2 concentrations. Quartiles 2,3, and 4 are represented by the green, blue, and purple lines respectively. We adjusted for demographics (age, sex, race, and ethnicity); CVD related factors (hypertension, diabetes mellitus, body mass index, history of CVD, baseline estimated glomerular filtration rate); transplant-related variables (pancreas transplant, and graft vintage at randomization); medications (lipid lowering drugs, cyclosporine, tacrolimus, sirolimus, mycophenolate, azathioprine, and prednisone); and urine albumin-to-creatinine ratio and randomization status.


  • NIDDK Support